Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935594 · ClinicalTrials.gov registry record · Phase 2
Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03935594 is a Phase 2 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT03935594, a Phase 2 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Hypertrophic burn scars are experienced by more than 70% of burn victims. They are a major source of decreased quality of life in burn patients due to pain, decreased range of motion, and poor cosmetic appearance. Current treatment strategies (including fat grafting and laser resurfacing) are either highly invasive, prohibitively costly, or painful. Autologous Platelet Rich Plasma (PRP) does not require anesthesia, and is an inexpensive, safe, fast, and less painful alternative that has been recognized for its role in reducing scars associated with acne, among other things. While PRP has not been studied specifically in burn scars, there is sufficient theoretical and practical evidence that it will improve the appearance and feel of these debilitating scars, representing a large potential benefit for these patients with minimal associated risk.
Interventions
- DRUG Saline Injection
- BIOLOGICAL PRP Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03935594
The ClinicalTrials.gov registry entry for NCT03935594 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline Injection is the first listed.
NCT03935594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03935594 about?
NCT03935594 is a clinical study titled "Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars". Hypertrophic burn scars are experienced by more than 70% of burn victims. They are a major source of decreased quality of life in burn patients due to pain, decreased range of motion, and poor cosmetic appearance. Current treatment strategies (including fat grafting and laser resurfacing) are either...
What is the current status of trial NCT03935594?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2020-09-18. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT03935594?
The interventions under investigation include: Saline Injection (DRUG), PRP Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT03935594?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.